ĐÁNH GIÁ TÌNH HÌNH GHÉP TẾ BÀO GỐC TẠO MÁU TỰ THÂN TẠI BỆNH VIỆN TRUNG ƯƠNG QUÂN ĐỘI 108 GIAI ĐOẠN 2024-2026

Objective: To evaluate the preliminary outcomes of autologous hematopoietic stem cell transplantation (ASCT) at 108 Military Central Hospital during the period 2024–2026.Subjects and methods: We conducted a retrospective study with post-transplant follow-up in patients with multiple myeloma and lymphoma who underwent ASCT between March 2024 and March 2026. A total of 37 patients received high-dose chemotherapy followed by ASCT, including 24 patients with multiple myeloma and 13 patients with lymphoma. All patients were followed until the end of the study period. The evaluated parameters included disease characteristics, infused CD34+ cell dose, time to neutrophil and platelet engraftment, transplant-related complications, and patient status as of March 2026.Results: Thirty-seven patients underwent ASCT, including 24 patients with multiple myeloma (64.9%) and 13 patients with lymphoma (35.1%). In the multiple myeloma group, the mean age at transplantation was 51.3 ± 6.3 years, with a male-to-female ratio of 2.4:1. Most patients achieved a very good partial response (VGPR) or partial response (PR) before transplantation. The mean infused stem cell dose was 5.4 × 10⁶ CD34+ cells/kg body weight. Mean times to neutrophil and platelet engraftment were 9.9 and 9.7 days, respectively. In the lymphoma group, 92.3% of patients achieved complete remission (CR) before transplantation. The mean infused stem cell dose was 5.9 × 10⁶ CD34+ cells/kg body weight. Mean times to neutrophil and platelet engraftment were 9.2 and 8.8 days, respectively.Successful engraftment was achieved in all patients. The most common complications were nausea and vomiting (86.5%), diarrhea (67.6%), and fever (54.1%). No transplant-related mortality was observed during hospitalization.Conclusion: Autologous hematopoietic stem cell transplantation at 108 Military Central Hospital was safely and effectively implemented, achieving a 100% engraftment rate, rapid hematologic recovery, and an acceptable toxicity profile.

Authors

Publication Details

Journal
Journal of Clinical Medicine Bach Mai Hospital
Published
2026-11-21
DOI
https://doi.org/10.52322/jocmbmh.156.0309
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ĐÁNH GIÁ TÌNH HÌNH GHÉP TẾ BÀO GỐC TẠO MÁU TỰ THÂN TẠI BỆNH VIỆN TRUNG ƯƠNG QUÂN ĐỘI 108 GIAI ĐOẠN 2024-2026

Văn Hiếu Phạm, Phạm Thị Tuyết Nhung, Thị Thanh Long Phan, Thanh Hương Nguyễn et al.
Journal of Clinical Medicine Bach Mai Hospital
Hematopoietic Stem Cell Transplantation
article

ĐÁNH GIÁ TÌNH HÌNH GHÉP TẾ BÀO GỐC TẠO MÁU TỰ THÂN TẠI BỆNH VIỆN TRUNG ƯƠNG QUÂN ĐỘI 108 GIAI ĐOẠN 2024-2026

Văn Hiếu Phạm, Phạm Thị Tuyết Nhung, Thị Thanh Long Phan, Thanh Hương Nguyễn, Thị Thu Huyền Lê, Thị Hương Giang Nguyễn
article en

Abstract

Objective: To evaluate the preliminary outcomes of autologous hematopoietic stem cell transplantation (ASCT) at 108 Military Central Hospital during the period 2024–2026.Subjects and methods: We conducted a retrospective study with post-transplant follow-up in patients with multiple myeloma and lymphoma who underwent ASCT between March 2024 and March 2026. A total of 37 patients received high-dose chemotherapy followed by ASCT, including 24 patients with multiple myeloma and 13 patients with lymphoma. All patients were followed until the end of the study period. The evaluated parameters included disease characteristics, infused CD34+ cell dose, time to neutrophil and platelet engraftment, transplant-related complications, and patient status as of March 2026.Results: Thirty-seven patients underwent ASCT, including 24 patients with multiple myeloma (64.9%) and 13 patients with lymphoma (35.1%). In the multiple myeloma group, the mean age at transplantation was 51.3 ± 6.3 years, with a male-to-female ratio of 2.4:1. Most patients achieved a very good partial response (VGPR) or partial response (PR) before transplantation. The mean infused stem cell dose was 5.4 × 10⁶ CD34+ cells/kg body weight. Mean times to neutrophil and platelet engraftment were 9.9 and 9.7 days, respectively. In the lymphoma group, 92.3% of patients achieved complete remission (CR) before transplantation. The mean infused stem cell dose was 5.9 × 10⁶ CD34+ cells/kg body weight. Mean times to neutrophil and platelet engraftment were 9.2 and 8.8 days, respectively.Successful engraftment was achieved in all patients. The most common complications were nausea and vomiting (86.5%), diarrhea (67.6%), and fever (54.1%). No transplant-related mortality was observed during hospitalization.Conclusion: Autologous hematopoietic stem cell transplantation at 108 Military Central Hospital was safely and effectively implemented, achieving a 100% engraftment rate, rapid hematologic recovery, and an acceptable toxicity profile.

Journal of Clinical Medicine Bach Mai HospitalVol. 3(156)
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon